Screener
Regeneron Pharmaceuticals REGN Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Regeneron Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Regeneron Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 6:52 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000872589-26-000025
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| 234.3 | 439.2 | 422.6 | 752.5 | |
| Income before income taxes | 1,527.8 | 1,518.7 | 2,359.0 | 2,423.7 |
| Income tax expense | 230.9 | 127.1 | 334.9 | 223.4 |
| Net income | $1,296.9 | $1,391.6 | $2,024.1 | $2,200.3 |
| Net income per share - basic | $12.62 | $13.24 | $19.58 | $20.78 |
| Net income per share - diluted | $12.23 | $12.81 | $18.95 | $20.02 |
| Weighted average shares outstanding - basic | 102.8 | 105.1 | 103.4 | 105.9 |
| Weighted average shares outstanding - diluted | 106.0 | 108.6 | 106.8 | 109.9 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Regeneron Pharmaceuticals's net income?
- Regeneron Pharmaceuticals (REGN) reported net income of $1.3B in Q2 2026.
- How has Regeneron Pharmaceuticals's net income changed year-over-year?
- Regeneron Pharmaceuticals's net income decreased by 6.8% year-over-year, from $1.39B to $1.3B.
- What is the long-term trend for Regeneron Pharmaceuticals's net income?
- Over 4 years (2021 to 2025), Regeneron Pharmaceuticals's net income has grown at a -13.6% compound annual growth rate (CAGR), from $8.08B to $4.5B.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Regeneron Pharmaceuticals's net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude